Fight like a Pro, with Prolaris®

Prolaris is an advanced genetic test that combines tools like Gleason score and PSA with a personalized tumor score to determine how aggressive your prostate cancer is. Prolaris helps you and your doctor decide the best treatment option based on your specific cancer.

Fight like a Pro, with Prolaris®

Prolaris is an advanced genetic test that combines tools like Gleason score and PSA with a personalized tumor score to determine how aggressive your prostate cancer is. Prolaris helps you and your doctor decide the best treatment option based on your specific cancer.

plays Prolaris explainer videolightbox

Is Prolaris right for me?

Prostate cancer is personal and treatment should be too. Prolaris is for any newly diagnosed man with prostate cancer and helps patients and providers answer pressing clinical questions like:

  • Are you safe for active surveillance or do you need treatment?
  • Is your cancer at risk of spreading?
  • What are your chances of surviving prostate cancer?
  • Can I benefit from adding hormone therapy (ADT) to radiation or can I safely avoid the side-effects of ADT?

Get our free testing guide

65%

In two clinical utility studies, Prolaris results lead to change in management in up to 65% of patients.1,2,3

2x

The Prolaris score is 2x more prognostic than PSA and Gleason score combined4

$0

97% of patients pay $0 out of pocket

Prolaris Patient story

Watch how Richard and his doctor worked together to decide on the best treatment option for him based on his Prolaris results.

Prolaris Patient story

Watch how Richard and his doctor worked together to decide on the best treatment option for him based on his Prolaris results.

Prostate Cancer can be a Hereditary Cancer

You may have inherited more than just your eye color from your parents

MyRisk is a genetic test that identifies hereditary (germline) mutations to determine if you have an inherited form of cancer. MyRisk helps high-risk or metastatic prostate cancer patients qualify for new, personalized treatments – like targeted medications, clinical trials or if you have an elevated risk of developing a secondary cancer.

Request test kit

Genetic insights that guide cancer treatment through every step of the journey

  • for newly diagnosed and untreated patients

    Prolaris® is a molecular diagnostic test that helps determine the aggressiveness of a prostate cancer tumor to determine if a patient can safely watch their cancer in favor of active surveillance or if they should pursue treatment.

  • for patients with a family history of cancer and/or advanced disease

    MyRisk is a germline test that offers a multi-gene panel to determine a patient’s risk of developing secondary cancers, as well as their children’s risk for the same germline mutations. MyRisk can also qualify patients for newer, personalized treatments such as targeted therapies and immunotherapy.

  • for advanced patients

    A somatic test that assesses 500+ genes, as well as key biomarkers like MSI, TMB and PD-L1, to determine if a patient’s tumor may be appropriate for novel therapies or clinical trials.

Previous Test
    Next Test

    Myriad is here for you

    Contact our trusted advisors for personalized support.

    Learn how genetic testing can provide better answers for the best prostate cancer treatment for you in our FREE Patient Testing Guide.

    References:

    1. Crawford ED, Scholz MC, Kar AJ, et al. Cell Cycle Progression Score and Treatment Decisions in Prostate Cancer:Results From an Ongoing Registry. Curr Med Res Opin 2014; 1-7
    2. Shore, N D., et al. Impact of the cell cycle progression test of physician and patient treatment selection for localized prostate cancer. The Journal of Urology 2016;195(3),612- 618
    3. Lin, D. W., et al. Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. Urologic Oncology: Seminars and Original Investigations. 2018; doi: 10.1016/j.urolonc.2018.03.011.
    4. Cuzick J, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. BJC 2012;106(6):1095-1099